GlassScriptPhysician profile
Nura Orra
NPI 1235585654
$907.31
in general payments reported to CMS, 2019-2025
19 companies · $89.32 in 2025
The $89.32 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $427 · 2020: $50.52 · 2021: $26.19 · 2022: $128 · 2023: $42.32 · 2024: $144 · 2025: $89.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $275.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $172.18 | 2019-2020 | |
| Abbvie INC. | $139.77 | 2020-2025 | |
| Abbott Laboratories | $73.54 | 2025 | Freestyle Libre 3 |
| Pfizer INC. | $65.94 | 2019-2021 | |
| Merz North America, INC. | $62.26 | 2022 | |
| Lilly USA, LLC | $62.15 | 2019-2024 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $52.84 | 2019-2024 | Verquvo |
| Novo Nordisk INC | $35.02 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.51 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.45 | 2019-2024 | Xifaxan |
| Glaxosmithkline, LLC. | $31.33 | 2019-2024 | Trelegy Ellipta |
| Allergan, INC. | $23.97 | 2019 | |
| Novartis Pharmaceuticals Corporation | $21.20 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.32 | 2019 | |
| Ironshore Pharmaceuticals INC. | $19.22 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $18.34 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $15.16 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.72 | 2021 | |
| Sanofi-Aventis U.S. LLC | $13.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nura Orra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.